EKEosu Kim

Eosu Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eosu Kim has a total of 346 co-authors. Here are the top co-authors by number of shared publications:

  • Hyunjeong Kim

    Department of Psychiatry, Laboratory for Alzheimer's Molecular Psychiatry, Institute of Behavioral Science in Medicine Yonsei University College of Medicine Seoul Republic of Korea

    16 shared publications
  • Chul Hoon Kim

    Department of Pharmacology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea

    13 shared publications
  • Jae-Jin Kim

    Institute of Behavioral Sciences in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Psychiatry, Yonsei University College of Medicine, Seoul, Republic of Korea

    13 shared publications
  • Kee Namkoong

    Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea

    13 shared publications
  • Jong Eun Lee

    Department of Anatomy, Yonsei University College of Medicine, Seoul, Republic of Korea

    12 shared publications
  • Ho-Taek Song

    Department of Radiology and Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul, Republic of Korea

    10 shared publications

Latest Publications

  • Open Access

    Evolving Alzheimer’s Disease Clinical Practice: Updated Diagnostic Criteria, Fluid Biomarkers, and Special Considerations for Anti-Amyloid Therapies

    by Hyun Woong Roh, Yoon Young Chang, Keun You Kim, So Yeon Jeon, Sheng-Min Wang, Eosu Kim, Jae-Nam Bae, Seung-Ho Ryu

    Objective This review overviewed the recent paradigm shifts in the diagnosis and management of Alzheimer’s disease (AD), emphasizing the 2024 Alzheimer’s Association (AA) revised criteria, advances in cerebrospinal fluid (CSF) and blood-based biomarkers (BBMs), and practical considerations for anti-amyloid monoclonal antibody therapy.Methods We conducted a narrative appraisal of consensus frameworks (2018 National Institute on Aging–Alzheimer’s Association [NIA-AA] amyloid, tau, and neurodegeneration [AT(N)] and the 2024 AA criteria), clinical practice guidance from AA released in 2025, regulatory status of CSF and BBMs. Intended-use settings (triage vs. confirmatory) of BBMs and implementation of anti-amyloid anti-body treatments (lecanemab or donanemab) in real-world practice in Korea were also reviewed.Results The 2024 AA criteria define AD biologically and designate A and T as core biomarkers; Core 1 biomarkers can establish AD irrespective of symptoms, whereas Core 2 biomarkers refine staging. A two-cutoff BBM strategy (positive/intermediate/negative) reduces misclassification and guides confirmatory CSF/positron emission tomography (PET) or retesting. BBMs now approach CSF/PET accuracy for amyloid detection, enable triage and, in selected settings, confirmation, and show utility for monitoring treatment response. Integration of clinical stages (1–6) with biological stages (A–D) clarifies syndrome–pathology discordance. Special scenarios—maintenance after induction, APOE ε4 homozygotes, Down syndrome, and serious mental illness—require individualized risk–benefit assessment. In South Korea, constrained access to tau PET and some BBMs necessitates Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision–anchored evaluation with selective biomarker testing.Conclusion Biomarker-oriented diagnosis and anti-amyloid therapies are reshaping AD care. Priorities include rigorous validation of BBMs across populations, equitable access to core biomarkers, safety strategies, and real-world evidence to implement maintenance and special-population care pathways.


  • Open Access

    Efficacy and Safety of Mobile App–Based Metamemory Cognitive Training for Mild Cognitive Impairment: Multicenter Randomized Clinical Trial

    by Sunyoung Kang, Jung-In Lim, Lukas Stenzel, Keun You Kim, Eosu Kim, Hong Jun Jeon, Doo-Heum Park, Hyun Kook Lim, YongSoo Shim, Jae-Won Jang, et al.

    Background: Metamemory training (MMT) offers a potential nonpharmacological approach to enhance cognitive function in individuals with mild cognitive impairment (MCI). While digital cognitive training improves accessibility, the effectiveness of mobile app–based MMT has not been evaluated in a randomized clinical trial. Objective: We aimed to evaluate the efficacy and safety of a mobile app–based MMT program, ET-101 (Cogthera), compared to a sham device control group in individuals with MCI. Methods: This multicenter, randomized controlled trial enrolled participants with MCI, recruited from 7 medical centers, and randomly assigned them to the ET-101 or control group (1:1 ratio). The intervention lasted 12 weeks, with a 12-week follow-up. The ET-101 group received metamemory-based multimemory strategy training and real-time feedback. Assessments of cognition, the daily activities of living, and the quality of life were conducted at baseline, week 12, and week 24. The primary outcome was the proportion of participants who showed cognitive improvement as assessed by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)-14 at weeks 12 and 24. Secondary outcomes included changes in the scores of scales assessing cognition, daily activities, and quality of life. Safety analysis assessed adverse events and their relation to digital therapeutics. Results: In the full analysis set, 49 participants were included in the ET-101 group and 50 in the control group. At week 24, the proportion of responders who maintained or improved their ADAS-Cog-14 scores was significantly higher in the ET-101 group than in the control group (P=.002). Additionally, the ET-101 group showed a significant improvement in ADAS-Cog-14 scores at week 24 compared to baseline levels (estimates=–2.53; t265=–3.05; Bonferroni-adjusted P=.003). A subdomain analysis revealed significant improvements in the memory (estimates=–2.50; t264=–4.03; Bonferroni-adjusted P<.001) and language (estimates=–0.807; t290=–3.68; Bonferroni-adjusted P<.001) domains at week 24 in the ET-101 group compared to the control group. In the safety analysis, 6 adverse events occurred in the ET-101 group and 4 in the control group, but none were related to the interventions. The attrition rate in the ET-101 group was 22.4% (11/49). Conclusions: ET-101 significantly improved cognitive function compared to the sham device, with effects observed not only in the memory domain but also in the language domain, indicating a transfer effect. Therefore, ET-101 has the potential to provide effective MMT to a broader population with MCI by overcoming location and personnel limitations through a mobile app–based platform. Trial Registration: ClinicalTrials.gov NCT05938426; https://clinicaltrials.gov/study/NCT05938426


  • Open Access

    Virtual reality-based cognitive assessment tools for mild cognitive impairment screening: comparison with traditional paper-and-pencil-based cognitive assessment tools

    by Seungryul Lee, Sooah Jang, Eosu Kim, Sang Joon Son, Woo Jung Kim, San Lee, Chang Hyung Hong, Hyun Woong Roh, Jeong-Ho Seok, Eunjin Jung, et al.

    Background and Objectives: Dementia is becoming increasingly prevalent, highlighting the need for early detection of mild cognitive impairment (MCI), a risk state for dementia. Traditional cognitive assessments often require trained examiners and lack ecological validity. This study examined the diagnostic accuracy of a virtual reality (VR)-based cognitive assessment tool, VARABOM.D, by comparing it with three standard tests: Seoul Neuropsychological Screening Battery (SNSB), Montreal Cognitive Assessment (MoCA), and Mini-Mental State Examination (MMSE). Research Design and Methods: Seventy-seven participants, divided into normal (n = 44) and MCI (n = 33) groups based on their Clinical Dementia Rating scores, completed the VARABOM.D program, in addition to SNSB, MoCA, and MMSE. Correlation analyses were performed on the test results, and the specificity, sensitivity, and area under the curve (AUC) of VARABOM.D were compared to those of the other assessments. To monitor for any adverse reactions to the VR environment, the Simulator Sickness Questionnaire (SSQ) was administered both before and after the VR sessions. Results: VARABOM.D scores showed significant positive associations with established cognitive assessments. Its AUC values were comparable to those of the MoCA, MMSE, and most SNSB subdomains except for attention, where VARABOM.D demonstrated greater discriminative ability. SSQ scores remained stable across pre- and post-VR sessions in both study groups, underscoring the VR platform’s safety and feasibility. Discussion and Implications: VARABOM.D demonstrated accuracy comparable to traditional cognitive assessments and even outperformed the attention subdomain of SNSB. Additionally, no adverse reactions were observed in the normal or MCI groups, further emphasizing the safety and stability of VARABOM.D.


  • Open Access

    Efficacy and Safety of Mobile App–Based Metamemory Cognitive Training for Mild Cognitive Impairment: Multicenter Randomized Clinical Trial (Preprint)

    by Sunyoung Kang, Jung-In Lim, Lukas Stenzel, Keun You Kim, Eosu Kim, Hong Jun Jeon, Doo-Heum Park, Hyun Kook Lim, YongSoo Shim, Jae-Won Jang, et al.

    BACKGROUND Metamemory training (MMT) offers a potential nonpharmacological approach to enhance cognitive function in individuals with mild cognitive impairment (MCI). While digital cognitive training improves accessibility, the effectiveness of mobile app–based MMT has not been evaluated in a randomized clinical trial. OBJECTIVE We aimed to evaluate the efficacy and safety of a mobile app–based MMT program, ET-101 (Cogthera), compared to a sham device control group in individuals with MCI. METHODS This multicenter, randomized controlled trial enrolled participants with MCI, recruited from 7 medical centers, and randomly assigned them to the ET-101 or control group (1:1 ratio). The intervention lasted 12 weeks, with a 12-week follow-up. The ET-101 group received metamemory-based multimemory strategy training and real-time feedback. Assessments of cognition, the daily activities of living, and the quality of life were conducted at baseline, week 12, and week 24. The primary outcome was the proportion of participants who showed cognitive improvement as assessed by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)-14 at weeks 12 and 24. Secondary outcomes included changes in the scores of scales assessing cognition, daily activities, and quality of life. Safety analysis assessed adverse events and their relation to digital therapeutics. RESULTS In the full analysis set, 49 participants were included in the ET-101 group and 50 in the control group. At week 24, the proportion of responders who maintained or improved their ADAS-Cog-14 scores was significantly higher in the ET-101 group than in the control group (P=.002). Additionally, the ET-101 group showed a significant improvement in ADAS-Cog-14 scores at week 24 compared to baseline levels (estimates=–2.53; t265=–3.05; Bonferroni-adjusted P=.003). A subdomain analysis revealed significant improvements in the memory (estimates=–2.50; t264=–4.03; Bonferroni-adjusted P<.001) and language (estimates=–0.807; t290=–3.68; Bonferroni-adjusted P<.001) domains at week 24 in the ET-101 group compared to the control group. In the safety analysis, 6 adverse events occurred in the ET-101 group and 4 in the control group, but none were related to the interventions. The attrition rate in the ET-101 group was 22.4% (11/49). CONCLUSIONS ET-101 significantly improved cognitive function compared to the sham device, with effects observed not only in the memory domain but also in the language domain, indicating a transfer effect. Therefore, ET-101 has the potential to provide effective MMT to a broader population with MCI by overcoming location and personnel limitations through a mobile app–based platform. CLINICALTRIAL ClinicalTrials.gov NCT05938426; https://clinicaltrials.gov/study/NCT05938426

  • Open Access

    Practical Guide of the Korean Association for Geriatric Psychiatry to Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Focused on Lecanemab

    by So Yeon Jeon, Sheng-Min Wang, Hyun Woong Roh, Keun You Kim, Yoon Young Chang, Eosu Kim, Jae-Nam Bae, Seung-Ho Ryu

    Jeon SY, et al. J Korean Med Sci. 2025 Jul;40:e215. https://doi.org/10.3346/jkms.2025.40.e215


  • Open Access

    Neural Effects of One’s Own Voice on Self-Talk for Emotion Regulation

    by Hye-Jeong Jo, Chanmi Park, Eunyoung Lee, Jee Hang Lee, Jinwoo Kim, Sujin Han, Joohan Kim, Eun Joo Kim, Eosu Kim, Jae-Jin Kim

    One’s own voice undergoes unique processing that distinguishes it from others’ voices, and thus listening to it may have a special neural basis for self-talk as an emotion regulation strategy. This study aimed to elucidate how neural effects of one’s own voice differ from those of others’ voices on the implementation of emotion regulation strategies. Twenty-one healthy adults were scanned using fMRI while listening to sentences synthesized in their own or others’ voices for self-affirmation and cognitive defusion, which were based on mental commitments to strengthen one’s positive aspects and imagining metaphoric actions to shake off negative aspects, respectively. The interaction effect between voice identity and strategy was observed in the superior temporal sulcus, middle temporal gyrus, and parahippocampal cortex, and activity in these regions showed that the uniqueness of one’s own voice is reflected more strongly for cognitive defusion than for self-affirmation. This interaction was also seen in the precuneus, suggesting intertwining of self-referential processing and episodic memory retrieval in self-affirmation with one’s own voice. These results imply that unique effects of one’s own voice may be expressed differently due to the degree of engagement of neural sharpening-related regions and self-referential networks depending on the type of emotion regulation.


  • Open Access

    Cholesterol profiling reveals 7β‐hydroxycholesterol as a pathologically relevant peripheral biomarker of Alzheimer's disease

    by Junghee Ha, Go Eun Kwon, Yumi Son, Soo Ah Jang, So Yeon Cho, Soo Jin Park, Hyunjeong Kim, Jimin Lee, Juseok Lee, Dongryul Seo, et al.

    Aim: Cholesterol homeostasis is associated with Alzheimer's disease (AD). Despite the multitude of cholesterol metabolites, little is known about which metabolites are directly involved in AD pathogenesis and can serve as its potential biomarkers.Methods: To identify “hit” metabolites, steroid profiling was conducted in mice with different age, diet, and genotype and also in humans with normal cognition, mild cognitive impairment, and AD using gas chromatography–mass spectrometry. Then, using one of the “hit” molecules (7β‐hydroxycholesterol; OHC), molecular and histopathological experiment and behavioral testing were conducted in normal mice following its intracranial stereotaxic injection to see whether this molecule drives AD pathogenesis and causes cognitive impairment.Results: The serum levels of several metabolites, including 7β‐OHC, were increased by aging in the 3xTg‐AD unlike normal mice. Consistently, the levels of 7β‐OHC were increased in the hairs of patients with AD and were correlated with clinical severity. We found that 7β‐OHC directly affects AD‐related pathophysiology; intrahippocampal injection of 7β‐OHC induced astrocyte and microglial cell activation, increased the levels of pro‐inflammatory cytokines (TNF‐alpha, IL‐1β, IL‐6), and enhanced amyloidogenic pathway. Mice treated with 7β‐OHC also exhibited deficits in memory and frontal/executive functions assessed by object recognition and 5‐choice serial reaction time task, respectively.Conclusions: Our results suggest that 7β‐OHC could serve as a convenient, peripheral biomarker of AD. As directly involved in AD pathogenesis, 7β‐OHC assay may help actualize personalized medicine in a way to identify an at‐risk subgroup as a candidate population for statin‐based AD treatment.


  • Top Cited Papers
    Open Access

    Developmental origin of oligodendrocytes determines their function in the adult brain

    by Sarah Foerster, Elisa M. Floriddia, David van Bruggen, Petra Kukanja, Bastien Hervé, Shangli Cheng, Eosu Kim, Benjamin U. Phillips, Christopher J. Heath, Richa B. Tripathi, et al.

    In the mouse embryonic forebrain, developmentally distinct oligodendrocyte progenitor cell populations and their progeny, oligodendrocytes, emerge from three distinct regions in a spatiotemporal gradient from ventral to dorsal. However, the functional importance of this oligodendrocyte developmental heterogeneity is unknown. Using a genetic strategy to ablate dorsally derived oligodendrocyte lineage cells (OLCs), we show here that the areas in which dorsally derived OLCs normally reside in the adult central nervous system become populated and myelinated by OLCs of ventral origin. These ectopic oligodendrocytes (eOLs) have a distinctive gene expression profile as well as subtle myelination abnormalities. The failure of eOLs to fully assume the role of the original dorsally derived cells results in locomotor and cognitive deficits in the adult animal. This study reveals the importance of developmental heterogeneity within the oligodendrocyte lineage and its importance for homeostatic brain function.


  • Open Access

    Reconsidering repurposing: long-term metformin treatment impairs cognition in Alzheimer’s model mice

    by So Yeon Cho, Eun Woo Kim, Soo Jin Park, Benjamin U. Phillips, Jihyeon Jeong, Hyunjeong Kim, Christopher J. Heath, Daehwan Kim, Yurim Jang, Laura López-Cruz, et al.

    Metformin, a primary anti-diabetic medication, has been anticipated to provide benefits for Alzheimer’s disease (AD), also known as “type 3 diabetes”. Nevertheless, some studies have demonstrated that metformin may trigger AD pathology and even elevate AD risk in humans. Despite this, limited research has elucidated the behavioral outcomes of metformin treatment, which would hold significant translational value. Thus, we aimed to perform thorough behavioral research on the prolonged administration of metformin to mice: We administered metformin (300 mg/kg/day) to transgenic 3xTg-AD and non-transgenic (NT) C57BL/6 mice over 1 and 2 years, respectively, and evaluated their behaviors across multiple domains via touchscreen operant chambers, including motivation, attention, memory, visual discrimination, and cognitive flexibility. We found metformin enhanced attention, inhibitory control, and associative learning in younger NT mice (≤16 months). However, chronic treatment led to impairments in memory retention and discrimination learning at older age. Furthermore, metformin caused learning and memory impairment and increased levels of AMPKα1-subunit, β-amyloid oligomers, plaques, phosphorylated tau, and GSK3β expression in AD mice. No changes in potential confounding factors on cognition, including levels of motivation, locomotion, appetite, body weight, blood glucose, and serum vitamin B12, were observed in metformin-treated AD mice. We also identified an enhanced amyloidogenic pathway in db/db mice, as well as in Neuro2a-APP695 cells and a decrease in synaptic markers, such as PSD-95 and synaptophysin in primary neurons, upon metformin treatment. Our findings collectively suggest that the repurposing of metformin should be carefully reconsidered when this drug is used for individuals with AD.